Puma Biotechnology (PBYI) Competitors

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Which has more risk & volatility, PBYI or ADMA?

Puma Biotechnology has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Do analysts rate PBYI or ADMA?

Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 33.69%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 85.78%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the media favor PBYI or ADMA?

In the previous week, Puma Biotechnology had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Puma Biotechnology and 4 mentions for ADMA Biologics. Puma Biotechnology's average media sentiment score of 1.20 beat ADMA Biologics' score of 0.70 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings & valuation, PBYI or ADMA?

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$230.50M	1.14	$30.28M	$0.98	5.34
ADMA Biologics	$426.45M	8.33	$197.67M	$0.86	17.32

Do insiders & institutionals have more ownership in PBYI or ADMA?

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 23.3% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is PBYI or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	20.38%	53.15%	23.51%
ADMA Biologics	44.06%	41.01%	28.47%

Summary

ADMA Biologics beats Puma Biotechnology on 11 of the 17 factors compared between the two stocks.